Dauntless Biotherapeutics, Inc.

San Diego, CA

UEI
LLU8TL82TYT3
CAGE
9CH38
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
9354 Pipilo St, San Diego, CA 92129, USA
Website
dauntlessbiotherapeutics.com
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Dauntless Biotherapeutics, Inc.'s latest federal award, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Overcoming breast cancer resistance with a dual-function antibody therapeutic - project summary metastatic breast cancer… Grant · R43CA306683 National Cancer Institute $400,000

Quick answers

What is Dauntless Biotherapeutics, Inc.'s UEI?

Dauntless Biotherapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is LLU8TL82TYT3.

What is Dauntless Biotherapeutics, Inc.'s CAGE code?

Dauntless Biotherapeutics, Inc.'s CAGE code is 9CH38.

What is Dauntless Biotherapeutics, Inc.'s primary NAICS code?

Dauntless Biotherapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Dauntless Biotherapeutics, Inc. located?

Dauntless Biotherapeutics, Inc.'s physical address in SAM.gov is 9354 Pipilo St, San Diego, CA 92129, USA.

Is Dauntless Biotherapeutics, Inc. registered in SAM.gov?

Yes. Dauntless Biotherapeutics, Inc.'s SAM.gov registration is active through March 2, 2027.

What is Dauntless Biotherapeutics, Inc.'s most recent federal award?

Dauntless Biotherapeutics, Inc.'s most recent federal grant award is Overcoming breast cancer resistance with a dual-function antibody therapeutic - project summary metastatic breast cancer… (R43CA306683), from National Cancer Institute, on August 11, 2026.

On GovTribe

See Dauntless Biotherapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login